XTL Biopharmaceuticals Receives Notification From NASDAQ Regarding Continuing Listing Requirements

Monday, October 23, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

RAANANA, Israel, Oct. 23, 2017 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) (TASE: XTLB.TA) ("XTL" or the "Company"),

a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases, today announced that on October 17, 2017, it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market
(the "Staff") indicating that the Company has failed to comply with the continued listing requirement that it maintain either a minimum of $2,500,000 in stockholders' equity or $35,000,000 market value of listed securities or $500,000 of net income from continuing operations for the most recently completed fiscal year or two of the three most recently completed fiscal years, and that the Staff is therefore reviewing the Company's eligibility for continued listing on The Nasdaq Capital Market. In accordance with Nasdaq's rules, the Company has 45 calendar days, or until December 1, 2017, to submit a plan to regain compliance. If the plan is accepted, Nasdaq can grant an extension of up to 180 calendar days from the date of the letter to evidence compliance. Based on the Company's internal review, it believes that it currently complies with such requirement due to the fact that as of September 30, 2017, the Company's stockholders' equity was approximately $3.6 million. The increase of stockholders equity from June 30, 2017 is mainly due to the financial income from the revaluation of the derivative (warrants to purchase ADS's).

The Company intends to respond to the Staff and provide the explanations for such compliance.

About XTL Biopharmaceuticals Ltd. (XTL)XTL Biopharmaceuticals Ltd., is a clinical-stage biotech company focused on the development of pharmaceutical products for the treatment of autoimmune diseases. The Company's lead drug candidate, hCDR1, is a world-class clinical asset for the treatment of autoimmune diseases including systemic lupus erythematosus (SLE) and Sjögren's Syndrome (SS). The few treatments currently on the market for these diseases are not effective enough for most patients and some have significant side effects. hCDR1 has robust clinical data in three clinical trials with 400 patients and over 200 preclinical studies with data published in more than 40 peer reviewed scientific journals.

XTL is traded on the Nasdaq Capital Market (NASDAQ: XTLB) and the Tel Aviv Stock Exchange (TASE: XTLB.TA). XTL shares are included in the following indices: Tel-Aviv Biomed, Tel-Aviv MidCap, and Tel-Aviv Tech Index.

Cautionary StatementThis press release may contain forward-looking statements, about XTL's expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, XTL or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as "believe," "expect," "intend," "plan," "may," "should" or "anticipate" or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by XTL with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of XTL's authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause XTL's actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause XTL's actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements, including, but not limited to, the factors summarized in XTL's filings with the SEC and in its periodic filings with the TASE. In addition, XTL operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control.  XTL does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise. Please see the risk factors associated with an investment in our ADSs or ordinary shares which are included in our Form 20-F-A filed with the U.S. Securities and Exchange Commission on April 3, 2017.

For further information, please contact:Investor Relations, XTL Biopharmaceuticals Ltd. Tel: +972 9 955 7080, Email: [email protected], www.xtlbio.com

View original content:http://www.prnewswire.com/news-releases/xtl-biopharmaceuticals-receives-notification-from-nasdaq-regarding-continuing-listing-requirements-300541181.html

SOURCE XTL Biopharmaceuticals Ltd



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store